MedTrace Logo

A Study to Evaluate the Relative Bioavailability and Tolerability of Bimekizumab in Healthy Subjects

NCT05028127 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2021-08-31

No results posted yet for this study

Summary

The purpose of the study to determine the relative bioavailability of bimekizumab in healthy subjects

Conditions

  • Healthy Volunteers

Interventions

DRUG

Bimekizumab

Subjects will be receiving bimekizumab at pre-specified time-points.

Sponsors & Collaborators

  • UCB Celltech

    lead INDUSTRY

Principal Investigators

  • UCB Cares · 001 844 599 2273 (UCB)

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-03-04
Primary Completion
2016-06-17
Completion
2016-06-17

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05028127 on ClinicalTrials.gov